"Ureteral Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.
| Descriptor ID |
D014516
|
| MeSH Number(s) |
C04.588.945.947.940 C12.758.820.875 C12.777.725.676 C13.351.937.820.875 C13.351.968.725.676
|
| Concept/Terms |
Ureteral Neoplasms- Ureteral Neoplasms
- Neoplasm, Ureteral
- Ureteral Neoplasm
- Neoplasms, Ureteral
- Ureter Neoplasms
- Ureter Neoplasm
- Neoplasms of Ureter
Cancer of Ureter- Cancer of Ureter
- Ureter Cancers
- Ureter, Cancer Of
- Ureter Cancer
- Ureteral Cancer
- Cancer, Ureteral
- Cancers, Ureteral
- Ureteral Cancers
- Cancer of the Ureter
|
Below are MeSH descriptors whose meaning is more general than "Ureteral Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Ureteral Neoplasms".
This graph shows the total number of publications written about "Ureteral Neoplasms" by people in this website by year, and whether "Ureteral Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 3 | 2 | 5 |
| 2009 | 9 | 2 | 11 |
| 2010 | 6 | 1 | 7 |
| 2011 | 2 | 0 | 2 |
| 2012 | 10 | 0 | 10 |
| 2013 | 4 | 0 | 4 |
| 2014 | 5 | 1 | 6 |
| 2015 | 3 | 0 | 3 |
| 2016 | 15 | 0 | 15 |
| 2017 | 6 | 1 | 7 |
| 2018 | 4 | 0 | 4 |
| 2019 | 7 | 0 | 7 |
| 2020 | 5 | 0 | 5 |
| 2021 | 8 | 1 | 9 |
| 2022 | 4 | 0 | 4 |
| 2023 | 6 | 0 | 6 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ureteral Neoplasms" by people in Profiles.
-
Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma. J Urol. 2024 Jun; 211(6):784-793.
-
Development and Validation of a Multivariable Nomogram Predictive of Post-Nephroureterectomy Renal Function. Eur Urol Oncol. 2024 Dec; 7(6):1313-1319.
-
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors. Urol Oncol. 2024 01; 42(1):20.e17-20.e23.
-
Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes. Eur Urol Focus. 2023 11; 9(6):1052-1058.
-
The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma. Urol Oncol. 2023 09; 41(9):387.e1-387.e7.
-
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline. J Urol. 2023 06; 209(6):1071-1081.
-
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. J Urol. 2023 05; 209(5):872-881.
-
Optimizing Lymph Node Dissection at the Time of Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. Eur Urol Focus. 2023 03; 9(2):280-282.
-
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes. Urol Oncol. 2023 03; 41(3):147.e15-147.e21.
-
Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study. BJU Int. 2023 04; 131(4):471-476.